

To,
The Manager,
Bombay Stock Exchange Ltd.
Dept. of Corporate Service
P J Towers, Dalal Street,
Mumbai-400001

Scrip Code;-537253 (BSE)

Sub: Investor Release for Quarter -1of FY 2016 -17


Dear Sir,

With reference to the above cited subject, please find enclosed the Quarter -1 FY 2016 Investor Release for your reference and Record.

This is your information and record please.

Thanking you.

Your Faithfully
For SUNIL HEALTHCARE LIMITED



Pawan Rathi
CFO

CC- Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata- 700 001

Sunil Healthcare Limited

Vijay Tower, 38E/252, - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049

T: +91 11 49435555/00 F: +91 11 43850087 e-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com

CIN No. L24302DL1973PLC189662

Q1-FY17 Revenue Growth at 27.6% YoY

EBITDA margin at 21.3%

PAT growth at 6.3% YoY

August 11th, 2016, New Delhi: Sunil Healthcare Ltd, a leading manufacturer of Empty Hard Gelatin Capsules, has announced its Un-audited Financial Results for the Quarter ended 30th June 2016.

Key Financial Highlights:

Rs. Million	Q1-FY17	Q1-FY16	Q4-FY 16	QoQ%	YoY%
Revenue	211.4	165.7	228.7	(7.6%)	27.6%
<i>Capsules</i>	211.4	165.7	176.0	20.1%	27.6%
<i>Marketing of Foods</i>	-	-	52.7	-	-
EBITDA	45.0	42.3	39.1	15.1%	6.3%
EBITDA Margin	21.3%	25.5%	17.1%	420 bps	(427 bps)
PBT	24.7	24.8	18.3	34.6%	(0.6%)
PAT	15.5	14.6	12.3	26.0%	6.4%
PAT Margin	7.3%	8.8%	5.4%	196 bps	(146 bps)
Cash PAT	25.9	23.6	23.5	10.2%	9.8%
Cash PAT Margin	12.3%	14.2%	10.3%	197 bps	(198 bps)

Our Profitability continues to be driven by our Capsules division and going forward the same shall be our core focus area for growth. The Capsules division performance is as follows –

Rs. Million	Q1-FY17	Q1-FY16	Q4-FY 16	QoQ%	YoY%
Revenue	211.4	165.7	176.0	20.1%	27.6%
EBITDA	46.0	42.8	31.8	44.8%	7.4%
EBITDA Margin	21.8%	25.8%	18.1%	371 bps	(408 bps)
PBT	25.7	25.3	11.0	132.7%	1.5%
PAT	16.2	14.9	7.4	118.4%	8.6%
PAT Margin	7.7%	9.0%	4.2%	344bps	(134bps)
Cash PAT	26.6	23.9	18.6	42.7%	11.2%
Cash PAT Margin	12.6%	14.4%	10.6%	199 bps	(185 bps)

Q1FY17 - Performance Highlights:

Since the past few months, the Capsule Industry is navigating through a challenging phase due to headwinds faced in the global markets on account of currency volatility, regulatory changes and payment challenges. Given this dynamic market scenario we have performed well. Our rigorous focus on optimizing our product mix coupled with cost control measures have led to a Revenue increase of 27.6% on YoY basis and 20.1% on QoQ basis. The increase



in Depreciation and Finance costs have resulted in lower growth in Profit after Tax, however as we ramp up operations we are confident of operating leverage benefits to enhance profitability.

The realizations in the Industry have remained muted in this quarter and we expect the same to continue going ahead. We shall however continue to focus on expanding our reach with existing and new clients.

We have also planned to foray in the USA market and in this direction have set up a wholly owned subsidiary by the name of Sunil Healthcare North America LLC.

Commenting on the results, Mr. D. Gnanasekaran (CEO) said, "We are pleased to report a positive start to FY17 with an increase in Revenue by 27.6% on a YoY basis. This increase is attributable to substantial volume growth achieved by the Company in the current quarter over previous quarters. Our continued focus on expanding our reach both in International and Domestic markets will help us outperform."

Brownfield Expansion for Capsules:

Our expansion plans remain on track, and we expect to ramp up capacity up to approximately 11.0 billion capsules/annum by the end of Q2FY17."

About Sunil Healthcare Ltd

Sunil Healthcare Ltd, is the second largest manufacturer of Empty Hard Gelatin Capsules in India. A Gol recognized Star Export House, ~50% of revenues are from exports. With four decades of experience, and a strong brand equity "Sunloc", the company is a preferred vendor for large pharmaceutical companies.

The company was the pioneer of Double lock and Triple lock technology in India. With a strong focus on R &D, the company is constantly innovating its product line to cater to the industry requirements.

For more information, please visit the company website www.sunilhealthcare.com

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors



For Further Details, Please Contact

Company :

Sunil Healthcare Ltd.
CIN - L24302DL1973PLC189662
Mr. Pawan Rathi, Chief Financial Officer

cfo@sunilhealthcare.com
www.sunilhealthcare.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Mr. Shogun Jain / Mrs. Payal Dave
+91 7738377756 / +91 9819916314
jshogun@sgapl.net / dpayal@sgapl.net
www.sgapl.net

